Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxycyte in severe non-penetrating traumatic brain injury
NCT00908063Phase 2
Key facts
- Status
- Terminated
- Start
- Oct 2009
- Primary completion
- Sep 2014
- Countries
- 2
- Sponsor
- Tenax Therapeutics
- Modality
- Nanoparticles, Small Molecules
- Conditions
- traumatic brain injury (TBI)
01
Overview
Phase 2, randomised, double-blind trial of perfluoro-tert-butylcyclohexane in traumatic brain injury (TBI) (2 arms), sponsored by Tenax Therapeutics. Primary endpoint: Safety and tolerability at Day 30. Started Oct 2009; status: terminated.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Oxycyte
Single intravenous infusion of Oxycyte (1.0, 2.0, or 3.0 mL/kg)
Normal Saline
Single intravenous infusion of Normal Saline
03
Who it enrols
Adult patients with severe non-penetrating TBI (GCS 4-8) able to be treated within 12 hours.
04
Endpoints
Primary
Safety and tolerability
Secondary
Efficacy as determined by short-term improvement
Beyond the preview
Go deeper on NCT00908063.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00908063.